DNA Damage Response (DDR) Drugs in Oncology Analysis 2022: Coverage of 399 Companies Plus Partners Developing 835 DDR Drugs with 412 in Active Development Across 226 Different Targets – QNT Press Release

DUBLIN, July 20, 2022 /PRNewswire/ — The “DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool” report has been added to ResearchAndMarkets.com’s offering.

DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool is the must have handbook for any business developer, BI/CI operative or clinical developer who needs to be on top of this hot and fast moving area of ​​oncology

This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your DDR drug surveillance and intelligence, allowing you to power your decision making and advance your own interests.

For 20 years we have supported better decision making across the oncology drug development industry. Your DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool is based on two decades of proven methodology and transforms your computer’s desktop into a high capacity workbench within your area of choice.

Even before launching this tool you have already eliminated the hundreds of hours of work needed to discover, process and piece together the thousands of sources that our team of oncology dedicated and highly experienced contents specialists have done on your behalf.

Your DNA Damage Response (DDR) Drugs in Oncology: Analytical Tool covers more than 399 companies plus partners who are today developing 835 DDR drugs where of 412 are in active development in cancer across 226 different targets.

Any data and/or analysis from the Analytical Tool is yours to keep and data/graphs/tables can be easily exported into Excel/PDF and various graphic formats for mixing …

Full story available on Benzinga.com

Source link

Recommended For You

About the Author: News Center